CHPA names new head of regulatory and scientific affairs

Pictured: Lisa Parks, RPh. Photo from CHPA.

The Consumer Healthcare Products Association (CHPA; Washington, DC) announced Lisa Parks, RPh, as its new senior vice president of regulatory and scientific affairs. Parks succeeds Barbara Kochanowski, PhD, who is retiring after nearly four decades in the consumer healthcare industry. Parks will start the position on June 5, 2023.

“Parks comes to CHPA with more than three decades of experience practicing pharmacy in retail and institutional settings, managing extensive cross-center organizational change at the U.S. Food and Drug Administration (FDA), and serving as the vice president of scientific and regulatory affairs at the generic industry’s Association for Accessible Medicines (AAM). Most recently, she served as a senior vice president of regulatory policy at Greenleaf Health, a leading FDA regulatory consulting firm,” the CHPA press release states. “Throughout her career, she has developed an expert understanding of FDA regulatory requirements and has significantly influenced regulatory strategy by serving as primary lead for the Generic Drug User Fee Amendments (GDUFA II & III) and her work on the regulatory and policy framework governing Abbreviated New Drug Application (ANDA) submissions.”